Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC11068 CLSP43 CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling.
DC21063 CM03 CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM).
DC12629 CM-675 CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively.
DC20913 CMA-008 CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM).
DC23813 CMC2.24 CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo.
DC7388 c-Met inhibitor 1 c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.
DC9617 CMK CMK is a RSK2 kinase inhibitor.
DC21530 CMP-5 Featured CMP-5 (PRMT5-IN-5) is a first-in-class, small-molecule inhibitor that specifically targets protein arginine methyltransferase 5 (PRMT5), an enzyme involved in epigenetic regulation and cellular signaling. PRMT5 catalyzes the symmetric dimethylation of arginine residues on histones and other proteins, playing a critical role in gene expression, cell proliferation, and survival. CMP-5 has shown remarkable specificity in blocking Epstein-Barr virus (EBV)-driven B-lymphocyte transformation and survival, while sparing normal B cells, making it a promising therapeutic candidate for EBV-associated cancers and other PRMT5-dependent diseases.
DC21531 CMP-5 hydrochloride CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells.
DC23508 CMPD167 CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM)..
DC22512 CMPDA Featured CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays.
DC12477 CN750 CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.
DC9370 CNP-AFU CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU).
DC7009 CNS-7056 CNS 7056 is a new short-acting sedative/anaesthetic that acts on GABAA receptors in the brain.
DC20346 CN-SAH CN-SAH is a potent and selective inhibitor of histone methyl transferase DOT1L with IC50 of 26 nM, displays >10-fold selectivity over DNMT1, PRMT3, PRMT5, and G9α..
DC12103 CNT2 inhibitor-1 CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.
DC23180 CNV1014802(Raxatrigine) Featured CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine, BIIB074) is a potent, selective Nav1.7 sodium channel blocker, shows analgesic effects and potential in the treatment of cognitive symptoms of schizophrenia in vivo.
DC7104 CNX-1351 CNX-1351 is a selective covalent Inhibitor of PI3Kα. CNX-1351 was tested against all four of the class I PI3K enzymes α, β, γ, and δ.
DC7105 CNX-2006 Featured CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
DC24119 Cobimetinib racemate Cobimetinib racemate is the racemate form of Cobimetinib (GDC-0973, XL518), which is a potent, highly selective inhibitor of MEK1/2..
DC22505 Cobimetinib R-enantiomer Cobimetinib R-enantiomer (GDC-0973.
DC11081 Coblopasvir Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection..
DC10430 COH29 COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with an IC50 of 8 μM in KB cell.
DC22149 COH-SR4 COH-SR4 (Mitochondria uncoupler SR4) is a bonafide uncoupler that induces energetic stress on cells, consequently leading to AMPK activation and mTOR inhibition without any effects on ERK/MEK MAPK signaling.
DC23785 Col 003 Col 003 is a small-molecule compound that inhibits the interaction of Hsp47 with collagen with IC50 of 1.8 uM, binds to the collagen-binding site on Hsp47.
DC7813 Collagen proline hydroxylase inhibitor Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents.
DC7608 OXi-4503 Combretastatin A1 diphosphate OXi4503 is the diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities.
DC11955 Takeda compound 101 Featured Compound 101 (GRK2 inhibitor 101, Takeda compound 101, Cmpd101) is a novel membrane-permeable, small-molecule inhibitor of GRK2 and GRK3.
DC10933 Compound 3-110-22 Compound 3-110-22 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E.
DC22270 Compound 621433144 Compound 621433144 (ZINC000621433144, Z3269026405) is a potent, selective full agonist of the D4 receptor with 2,500-fold subtype selectivity.

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X